Dabrafenib–trametinib combination receives anaplastic thyroid cancer approval
medwireNews: Dabrafenib plus trametinib have received a further approval from the US FDA, this time for the treatment of metastatic anaplastic thyroid cancer harboring a BRAF V600E mutation.
The decision follows the recent announcement on the adjuvant use of the BRAF inhibitor and MEK inhibitor combination in patients with mutated melanoma and an earlier decision to approve the treatment for BRAF V600-positive non-small-cell lung cancer.
“This approval demonstrates that targeting the same molecular pathway in diverse diseases is an effective way to expedite the development of treatments that may help more patients”, commented Richard Pazdur, from the FDA’s Center for Drug Evaluation and Research in a press release.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group